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In this article of EBioMedicine, Chunxia Liu and colleagues [1] show
that guanine nucleotide exchange factor T (GEFT) overexpression in
rhabdomyosarcoma (RMS) cell lines and patients’ biopsies is correlated
to the methylation status of its promoter region, which is significantly
lower in RMS tumours than in normal skeletal muscle, this strictly link-
ing epigenetic aberrations to malignant phenotype. Indeed, epigeneti-
cally mediated upregulation of GEFT, a protein involved in Rho-GTPase
activation [2], is shown to promote growth, progression and metastasis
of RMS cells by controlling specific mediators of the epithelial-mesen-
chymal transition (EMT) and mesenchymal-epithelial transition (MET)
processes, both in vitro and in xenograft mouse models. Specifically, the
authors indicate that GEFT functions in RMS tumorigenicity are corre-
lated with the aberrant modulation of the Rac1/Cdc42-PAK1 signalling
pathway and its interrelated genes. Altogether, the reported findings
are particularly interesting since they provide new insights into the
molecular mechanisms involved in the metastatic capacity of RMS can-
cer cells. In addition to this, they have the translational potential for
future personalised therapies, since they propose new possible targets
for setting advanced therapeutic strategies against RMS tumours.
To better understand the relevance of the scientific data reported
by Liu et al., [1] it is essential to underline the importance of epigenetic
modifications in cancer progression, mainly in RMS dissemination.
RMS is the most frequently diagnosed malignant soft tissue sarcoma
in children and adolescents [3]. The two main histological subtypes in
childhood are alveolar RMS (ARMS) and embryonal RMS (ERMS), which
are characterised by distinct clinicopathological features and outcomes
[4]. RMS is particularly aggressive and patients with metastatic or recur-
rent disease have a poor clinical outcome with a 5-year overall survival
of about 30%. Hence, the identification of innovative therapies against
advanced RMS represents an urgent clinical need.
Tumours commonly share mutations in pivotal genes mainly
implicated in cell proliferation and survival, but it is increasinglyE-mail address: francesca.megiorni@uniroma1.it
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ation, histone modifications and non-coding RNAs (ncRNAs), is a hall-
mark of many different malignancies. This is particularly true for RMS
neoplasia, which is characterized by few specific genetic alterations,
such as PAX3/7-FOXO1 translocations in ARMSs and RAS family-
related mutations in ERMSs, being essentially defined by an aberrant
epigenetic landscape. Indeed, altered expression of DNA methyl-
transferases and demethylases, enzymes involved in histone acetyla-
tion, methylation and phosphorylation as well as microRNAs, long
non-coding and circular RNAs have been reported in RMS tumours
[59]. In turn, due to the important impact in the regulation of gene
expression at transcriptional and post-transcriptional levels, deregu-
lation of epigenetic components alters a wide range of genes related
to cell growth, differentiation, DNA replication, EMT/MET, migration,
invasion and survival. So, epigenetic reprogramming appears to be a
key challenge in the fight against RMS cancer and the identification
of novel druggable targets represents the major goal for many biolo-
gists and clinicians. In recent years, several anticancer epigenetic
drugs, the so called “epi‑drugs”, have been tested as single agents
than in combination with conventional treatments, i.e. chemotherapy
and radiotherapy, with the ambition to critically block cancer cell
proliferation and reduce any mechanisms of tumour resistance
[8,10]. Anyway, many epigenetic therapies, already approved by U.S.
Food and Drug Administration, are represented by DNA demethylat-
ing agents and histone deacetylase inhibitors that may act on a broad
range of coding and non-coding genes, potentially leading to unex-
pected side effects [10]. To this concern, the definition of specific epi-
genetically modified genes and precise molecular mechanisms
playing role in their aberrant expression may represent a more
focused solution that can help setting a novel generation of antitu-
moral molecules, designed to have maximal therapeutic efficacy and
minimal toxicity with the final aim to improve safety and clinical out-
comes of patients in near future. In their work, Liu et al. [1] underline
the crucial role of epigenetic landscape in EMT/MET induction to sus-
tain RMS tumour metastases and indicate that these processes are
specifically associated with a marked DNA hypomethylation of the
GEFT gene, which in turn influences the expression of EMT/MET-
related factors by modulating the Rac1/Cdc42-PAK1 pathway. Indeed,
the authors speculate that the epigenetic modification associated
with the GEFT promoter region may have clinical applications by rep-
resenting a potential biomarker for accurate RMS diagnostic evalua-
tion, cancer staging and risk stratification. Accordingly, methylation
levels at GEFT promoter region significantly correlated with RMSder the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2 F. Megiorni / EBioMedicine 52 (2020) 102673clinical pathological characteristics. Therefore, normalization of GEFT
expression by a correct epigenetic reprogramming is suggested as a
new therapeutic opportunity in the treatment of RMS patients, fur-
ther outlining the importance to move epigenetic modifications from
bench to bedside.
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